Tuesday, Alkermes plc (ALKS) announced positive topline results from the REVITALYZ phase 3 study, evaluating the investigational use of LUMRYZ extended-release oral suspension in adults with idiopathic hypersomnia.
The company stated that LUMRYZ met the primary endpoint by showing statistically significant improvements in excessive daytime sleepiness compared to placebo as measured by the change in Epworth Sleepiness Scale score.
Moreover, the safety profile of LUMRYZ in the REVITALYZ study was generally consistent with previously observed safety data associated with LUMRYZ, with no new safety signals observed in this population.
Moving ahead, the company plans to file a supplemental New Drug Application with the U.S. Food and Drug Administration by 2026 end.
In the pre-market hours, ALKS is trading at $36.39, up 2.59 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.